News Gilead tags Merck for first-line triple negative breast canc... Take two recently-approved immunotherapies for triple negative breast cancer (TNBC), put them together, and what do you get?
News Gilead scores US approval for breast cancer drug that wowed ... Gilead’s $21 billion purchase of Immunomedics and its potential blockbuster Trodelvy continues to pay off, as the drug has now been approved by the FDA for triple-negative breast cancer.
News Gilead claims first FDA nod for a hepatitis D therapy At its second attempt, Gilead has won FDA approval for chronic hepatitis D virus drug Hepcludex, four years after it was cleared in the EU.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.